Certara Announces Proposed Public Offering of Common Stock
Certara, Inc. announced a proposed underwritten public offering of 17 million shares of its common stock by selling stockholders, with an additional 2,550,000 shares available for purchase by underwriters. Certara will not receive proceeds from this offering. The underwriting team includes Jefferies, Morgan Stanley, and BofA Securities. A preliminary registration statement has been filed with the SEC but is not yet effective, meaning no sales can occur until it is approved. This initiative supports Certara's ongoing role in biosimulation technology for drug development.
- Proposed offering of 17 million shares could enhance liquidity for selling stockholders.
- Involvement of major underwriters (Jefferies, Morgan Stanley, BofA Securities) reflects confidence in the stock.
- Certara will not receive any proceeds from the offering, limiting potential growth capital.
- The offering could lead to share dilution for existing shareholders if additional shares are sold.
Certara, Inc. (“Certara”), a global leader in biosimulation, today announced a proposed underwritten public offering of 17 million shares of its common stock being offered by selling stockholders. Additionally, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to 2,550,000 additional shares of common stock. Certara will not receive any proceeds from the sale of shares in the offering by the selling stockholders.
The offering is being made through an underwriting group led by Jefferies, Morgan Stanley and BofA Securities, who are acting as lead joint book-running managers.
A registration statement on Form S-1, including a prospectus, which is preliminary and subject to completion, relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering may be made only by means of a prospectus. Copies of the preliminary prospectus may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 547-6340 or by email at Prospectus_Department@jefferies.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; or BofA Securities, Inc., NC1-004-03-43, Attention: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, NC 29255, by telephone at (800) 294-1322 or by email at dg.prospectus_requests@bofa.com.
About Certara
Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210322005799/en/
FAQ
What is the size of the stock offering by Certara (CERT)?
Who are the underwriters for Certara's stock offering?
Will Certara receive proceeds from the stock offering?
What is the purpose of Certara's proposed stock offering?
Is the registration statement for Certara's offering effective?
